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Abstract: Ribonucleases are a superfamily of enzymes which operate at the crossroads of 
transcription and translation, catalyzing the degradation of RNA; they can be cytotoxic because 
the cleavage of RNA renders indecipherable its information. Ranpirnase is a novel ribonuclease 
which preferentially degrades tRNA, thus leading to inhibition of protein synthesis and, ulti-
mately, to cytostasis and cytotoxicity. Ranpirnase has demonstrated antitumor activity both in 
vitro and in vivo in several tumor models. The maximum tolerated dose emerging from phase I 
studies was 960 g/m2, with renal toxicity as the main dose-limiting toxicity. A large phase II 
trial showed that ranpirnase has disease-modifying activity against malignant mesothelioma. 
Ranpirnase proved to be superior to doxorubicin in a phase III trial, while preliminary results 
of another large, phase III trial, suggest that the combination of ranpirnase and doxorubicin 
could be more effective than doxorubicin alone. In all the above studies, ranpirnase seems to act 
mainly as a cytostatic rather than a cytotoxic drug, stabilizing progressive disease and potentially 
prolonging patients’ survival. Ranpirnase may thus ﬁ  nd its niche in combination with doxorubicin 
for mesothelioma as a second-line therapy, where no standard of care presently exists.
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Malignant mesothelioma: still an orphan disease
The incidence of malignant mesothelioma (MMe), a relatively rare cancer linked 
to asbestos exposure, is expected to increase dramatically over the next couple of 
decades, both in Europe and in many developing countries (Peto et al 1999; Carbone 
et al 2007).
The vast majority of MMe patients present with stage III or IV, ie, mainly unresect-
able, disease; despite some recent advance in the medical treatment of MMe, presently 
the aim of the treatment for these patients is only palliation (Vogelzang et al 2005; 
Fennell et al 2008). A few randomized controlled trials have ﬁ  rmly established the use 
of antifolate-platinum doublets as the present treatment of choice for locally advanced 
unresectable or metastatic MMe patients, supporting the evidence from meta-analyses 
for the superior activity of platinum-based combinations (Fennell et al 2008).
Even though, theoretically, second-line therapy of MMe might have an important 
role in increasing survival rates, no standards have emerged so far in this setting.
Taken together, the unsatisfactory results obtained with ﬁ  rst-line treatment options, 
and the lack of a standard of treatment for those patients who, still being in good 
condition, progress after a ﬁ  rst-line treatment, emphasize the need for newer, active, 
agents for such a disease.
An historic introduction to ribonucleases
Ribonucleases, which were extensively studied in the 1960s and 1970s, are a family 
of enzymes well known for their physiological ability to cleave RNA; indeed, bovine Biologics: Targets & Therapy 2008:2(4) 602
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pancreatic ribonuclease, or RNase A, has been used as 
a privileged model in protein folding studies. After this 
early enthusiasm, ribonucleases were almost dismissed as 
uninteresting digestive enzymes. Only recently have they 
attracted attention again, owing to their remarkable and 
complex biological activities (Leland and Raines 2001; 
Benito et al 2005; Arnold and Ulbrich-Hofmann 2006; Lee 
and Raines 2008).
As a whole, ribonucleases are a superfamily of secretory 
enzymes that operate at the crossroads of transcription and 
translation, catalyzing the degradation of RNA; however, 
several other intriguing activities have been described 
recently. For example, angiogenin is able to promote angio-
genesis (Riordan 1997), and bovine seminal ribonuclease, 
a unique dimeric homolog of RNase A, has relevant immu-
nosuppressive and antitumor activities, as well as being 
embriotoxic and aspermatogenic (D’Alessio et al 1997).
Ribonucleases: a novel 
class of anticancer targeted agents
Ribonucleases can be cytotoxic due to the fact that the 
cleavage of RNA renders indecipherable the information 
it encodes.
For years, replicative DNA was the main target of 
anticancer agents; more recently, speciﬁ  c proteins endowed 
with receptor and/or signal transduction properties have 
become the main target of anticancer agents; RNA, which 
is in between DNA and proteins (Figure 1), only rarely has 
been the target of anticancer drugs (Bruserud 2007), and 
even then with only modest relevance, as in the case of 5-FU 
antitumor activity.
The cytotoxicity of pancreatic-type ribonucleases was 
ﬁ  rst discovered and described in the early 1950s, when RNase 
A was shown to be toxic to tumor cells in vitro (Ledoux and 
Balthus 1954) as well as in in vivo models (Ledoux 1955).
Ranpirnase
Pharmacology and mechanism of action
Ranpirnase (P-30 protein [Onconase®], Alfacell Corp, 
Bloomﬁ  eld, NJ, USA) is a novel ribonuclease which, as a 
homolog of RNase A, belongs to the family of pancreatic 
ribonucleases (Ardelt et al 1991); however, it is present in 
the oocytes and early embryos of Rana pipiens, the Northern 
Leopard frog (Irie et al 1998). It is a single-chain protein, 104 
amino acid residues long, with a molecular weight of about 
12,000 Da (Ardelt et al 1991), an amino acid sequence ∼30% 
identical to that of RNase A (Ardelt et al 1991), and 
molecular structure similar to that of RNase A (Mosimann 
et al 1992). Owing to the presence of 4 disulﬁ  de bonds, 3 of 
which are conserved in RNase A, it is highly stable to heat, 
RNA RNA DNA DNA protein protein
transcription transcription translation translation
nucleotides nucleotides
degradation degradation
by ribonucleases by ribonucleases
“ “Traditional Traditional” ” chemotherapy chemotherapy
R R
K K
“ “New New” ” target  target therapies therapies
Ribonucleases  Ribonucleases (e.g.,  (e.g., Ranpirnase Ranpirnase) )
G
G
G
G
C
C
C
C
C
A T
T
T
T
T
T
T
T
T
A
A
A
A
A
A
G
G
Figure 1 Anticancer agents usually target either DNA or proteins endowed with receptor and/or signal transduction properties. However, RNA, which is in between DNA 
and proteins, could also be targeted effectively by speciﬁ  c anticancer drugs such as ranpirnase.Biologics: Targets & Therapy 2008:2(4) 603
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with a midpoint temperature of thermal denaturation (Tm) 
of 90 °C, almost 30 °C higher than that of RNase A (Leland 
et al 1998).
Ranpirnase binds to the cell surface and uses the 
energy-dependent endocytic process to penetrate into the 
cell (Wu et al 1993), routed through the Golgi apparatus to 
the cytosol, where it preferentially degrades tRNA (but not 
ribosmal and mRNA) by catalyzing the cleavage of the P-O5′ 
bond of RNA on the 3′ side of pyrimidine nucleosides 
(Iordanov et al 2000a).
This RNA degradation leads to inhibition of protein 
synthesis and, ultimately, to the cytostatic and cytotoxic 
activity of ranpirnase. Indeed, ranpirnase plays a cytostatic 
role, arresting the cell cycle in G1 (Darzynkiewicz et al 
1988; Juan et al 1998), as well as a cytotoxic role, acting as a 
cytotoxin (Wu et al 1993). Evidence suggests that the irrepa-
rable tRNA damage induced by ranpirnase may constitute a 
pro-apoptotic signal (Iordanov et al 2000a); the apoptosis trig-
gered by ranpirnase seems to be mainly caspase-dependent, 
even though a caspase-independent mechanism has been 
recently described (Michaelis et al 2007). Furthermore, p53 
status does not affect ranpirnase-induced apoptosis (Costanzi 
et al 2005), a key feature of ranpirnase, since it is well known 
that many tumors carry an inactivated p53, which, in turn, 
can suppress or reduce the apopototic process activated by 
several chemotherapeutic agents.
The superior activity of ranpirnase on tumor cells, 
compared with normal cells, has been explained molecularly 
by an elegant in vitro study by Iordanov et al (2000b), in 
which the authors investigated whether ranpirnase activates 
two signal-transduction pathways commonly stimulated 
by conventional chemo- and radio-therapy, ie, the stress-
activated protein kinase (SAPK) and the nuclear factor-kB 
(NFkB) pathways. Ranpirnase proved to be a potent acti-
vator of SAPK1 (JNK-1 and -2) and SAPK2 (p38 MAP 
kinase), but not NFkB; using explanted ﬁ  broblasts from 
mice containing targeted disruption of both jnk-1 and -2 
alleles, the authors found that JNKs are important media-
tors of ranpirnase-induced cytotoxicity. Surprisingly, after 
immortalization of these same cells with human papilloma 
virus 16 (HPV 16) gene products E6 and E7, additional 
proapoptotic pathways were activated, thus suggesting that, 
in cancer cells, ranpirnase is more proapoptotic, inducing 
several different pathways.
Notably, ranprinase proved not to be a substrate for the 
MDR1 gene product p-glycoprotein (pGP), one of the major 
factors responsible for resistance to cytotoxic chemotherapy; 
indeed, at least one in vitro study demonstrated that the 
cytotoxic effect of ranpirnase was unrelated to P-gp 
expression levels, with an IC50 of approximately 6 × 10−5 M 
in both wild-type as well as MDR1-transfects cancer cells 
(Rybak et al 1996).
Ribonuclease activity is regulated by the presence of 
cytosolic, class-speciﬁ  c, inhibitors of its enzymatic activity, 
globally known as ribonuclease inhibitor (RI). Even though 
the precise biological role of these inhibitors is still far from 
perfectly known, they act to protect cellular RNA if a ribo-
nuclease inadvertently enters the cytosol (Hofsteenge 1997); 
remarkably, RI is not so powerful in inhibiting ranpirnase 
catalysis (Leland and Raines 2001). Indeed, the Ki value for 
the inhibition of ranpirnase by RI is estimated to be 10−6 M, 
which is more than 107-fold greater than the Kd value for the 
RI-RNase A complex (Boix et al 1996).
Further insights into the antitumor activity of ranprinase 
have been reported recently. Ardelt et al (2007) suggested that 
ranprinase is able to decrease the generation of reactive oxygen 
species, as well as the mitochondrial transmembrane potential 
in vitro, and that such a suppression of intracellular oxida-
tive stress may contribute to the cytotoxic and pro-apoptotic 
activity of the drug, when combined with cytotoxic agents); 
indeed, even though oxidative stress is generally regarded 
as pro-apoptotic, it may also interfere with cancer chemo-
therapy, as demonstrated in a Burkitt’s lymphoma model, 
where apoptosis induced by several chemotherapeutic agents, 
including doxorubicin, was inhibited by hydrogen peroxide 
(Shacter et al 2000). Therefore, the antioxidative function of 
ranpirnase has been regarded as an important element of its 
antiproliferative/cytotoxic activity towards cancer cells, and 
a possible mechanism of its well-documented synergism with 
other anticancer agents (Mikulski et al 1990, 1992; Rybak 
et al 1996; Deptala et al 1998).
Other studies suggest that ranpirnase could also act as a 
radiation sensitizer (Lee et al 2007a), and that such a novel 
activity is due, on the one hand, to the inhibition of oxygen 
consumption (QO2) and, on the other, to the inhibition of sub-
lethal damage repair, both in vitro and in vivo in a xenograft 
model of lung cancer (Lee et al 2000a; Kim et al 2007).
Finally, another recent study demonstrated that multiple, 
small doses of ranpirnase increased apoptosis and cytotoxicty 
of A549 non-small-cell lung cancer, both in vitro (Lee et al 
2007b) and in vivo (Lee and Shogen 2008), thus suggesting 
the use of alternative schedules of the drug.
Preclinical activity
In vitro, ranpirnase has demonstrated both cytostatic and 
cytotoxic effects on several murine and human cell lines Biologics: Targets & Therapy 2008:2(4) 604
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(Costanzi et al 2005; Pavlakis and Vogelzang 2006), as a 
single-agent, as well as in combination with other agents. 
The prevalent type of response to ranpirnase observed 
in established human cancer cell lines is summarized in 
Table 1.
Against MMe cell lines, ranpirnase has been shown 
to inhibit cell growth, both in vitro and in vivo (Costanzi 
et al 2005); indeed, it proved able to prolong survival of 
tumor-bearing mice, compared with controls, an activity that 
has been documented in many different xenograft models 
(Costanzi et al 2005). Table 2 summarizes ranprinase activity 
in different animal models.
Enhanced cytotoxicity has been seen with co-
administration of ranpirnase with several anticancer drugs, 
including tamoxifen (Mikulski et al 1990, 1992), cisplatin 
(Mikulski et al 1992; Lee et al 2007b), doxorubicin (Mikulski 
et al 1999), vincristine (Rybak et al 1996), and also with 
phosphatidyl inositol-3 kinase inhibitors (Ramos-Nino 
et al 2005).
Biodistribution and toxic effects 
in animals
Biodistribution studies in mice have shown that iv ranpir-
nase is taken up primarily by the kidneys (60%–70% of 
injected dose at 15 minutes), while liver uptake is minimal, 
although prolonged retention by the liver has been observed 
(Vasandani et al 1996). In the kidney, after 1 week of treat-
ment, and more evidently after 3 weeks, there was evidence 
of acute moderate multifocal proximal renal tubular necrosis, 
a toxicity that was reversed 2 weeks after drug withdrawal; 
in the liver, toxic effects (once again reversibile) were seen 
in the hepatocytes, with lipidosis, cellular swelling, vacuolar 
degeneration and apoptosis in mice treated for 1 or 3 weeks 
(Vasandani et al 1999).
Phase I studies
Two phase I studies evaluating the optimum dose and 
schedule of ranpirnase have been performed. In the ﬁ  rst of 
these studies, ranpirnase was studied using a daily schedule 
of iv administration beginning at 6 g/m2/day and closing at 
105 g/m2/day, without determining a maximum tolerated dose 
(MTD). One patient developed renal failure requiring dialysis 
at the dose level of 80 g/m2. Three (9.3%) of the 32 patients 
enrolled showed disease stabilization as their best response 
to treatment (Costanzi et al 2005).
In the second phase I study, ranpirnase was administered iv 
as a single agent on a weekly schedule at 5 dose levels, in the 
range of 60–1200 g/m2. A total of 71 patients were thus treated, 
and the MTD was established as 960 g/m2. In this study, some 
objective responses were observed in lung cancer (1 partial 
response), esophageal carcinoma (1 partial response), and 
colorectal carcinoma (1 minor response) patients, while stable 
diseases were observed in other patients with different tumors. 
Thus, the recommended phase II dose using this weekly 
schedule was 480 g/m2/week (Mikulski et al 1993).
In the phase I study of the weekly schedule, the dose-
limiting toxicity was renal, manifested by proteinuria with 
or without azotemia, peripheral edema, and fatigue. Other 
toxicities included ﬂ  ushing, myalgias, transient dizziness, and 
decreased appetite. Transient hypotensive reactions preceded 
by ﬂ  ushing that responded quickly to volume expansion 
were also observed. Notably, no signiﬁ  cant myelosuppres-
sion, mucositis, alopecia, cardiotoxicity, coagulopathy, or 
hepatotoxicity was observed.
Table 1 Prevalent type of response to ranpirnase observed in established human cancer cell lines in vitro
Human cell line Author Prevalent type of response 
to ranpirnase observed
A549 (NSCLC) Lee et al 2000 cytotoxic
ASPC-1 (pancreas)
HepG2 (hepatoma)
LS174T (colon)
U937 (lymphoma) Halicka et al 1996 pro-apoptotic
HL 60 (leukemia)
Colo 320 CM (colon) Darzynkiewicz 
et al 1988
cell cycle delay (all phases) or arrest
A-253 (submaxillary 
carcinoma)
HL 60 (leukemia)
U937 (histocytic lymphoma) Juan et al 1998 cell cycle arrest in G1Biologics: Targets & Therapy 2008:2(4) 605
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Phase II studies in tumors other than 
mesothelioma
Ranpirnase has been studied in phase II trials as a single 
agent in patients with non-small-cell lung cancer (Costanzi 
et al 1995; Mikulski et al 1995), breast cancer (Puccio et al 
1996), and renal cell cancer (Vogelzang et al 1999), and in 
combination with tamoxifen in pancreatic (Chun et al 1995) 
and prostate cancer (Costanzi et al 2005).
In the preliminary report of the phase II study in 
non-small-cell lung cancer, ranpirnase (given at 240 g/m2) 
as a single agent induced no objective responses in the 
30 patients evaluated; however, 5 patients (17%) achieved 
disease stabilization, with a resulting median survival time 
of 7.7 months (Costanzi et al 1995; Mikulski et al 1995).
A small study, reported in abstract form (Puccio et al 1996), 
demonstrated a limited clinical beneﬁ  t in breast cancer (1 minor 
response and 2 disease stabilizations out of 17 patients).
In 14 patients with refractory advanced renal cell cancer, 
ranpirnase, given at a dose of 480 g/m2/week, proved to be 
inactive in terms of antitumor activity, but yielded encour-
aging results in terms of median survival time (Vogelzang 
et al 1999).
In a phase I/II pancreatic cancer study, ranpirnase 
recommended dose was 480 mg/m2, while tamoxifen was 
started 7 days prior the ﬁ  rst ranpirnase dose to allow for the 
accumulation of the drug within the tumor, as suggested by a 
pre-clinical model; such a combination yielded 1 complete, 
2 minor responses, and 7 disease stabilizations out of 32 evalu-
able patients, suggesting a potential activity of the combination 
in pancreatic cancer (Chun et al 1995; Costanzi et al 2005).
Another study addressed the antitumor activity of 
ranpirnase when given in combination with tamoxifen in 
patients with early prostate cancer recurrence, as evidenced 
by rising prostate speciﬁ  c antigen (PSA) test after prostatec-
tomy or radiation therapy. The study has not been reported in 
extenso so far, having been addressed only within the review 
by Costanzi et al (2005). Among the 13 patiente enrolled in this 
small study, 6 discontinued treatment owing to toxicity before 
completing 3 cycles of treatment, and only 1 patient showed 
stable PSA levels, suggesting an extremely low activity of the 
of the ranpirnase/tamoxifen combination in this setting.
Phase II study in malignant mesothelioma
A single-arm, open-label, multicenter phase II trial of ranpir-
nase as a single agent has been performed in MMe patients, 
the largest phase II study of this drug undertaken (Mikulski 
et al 2002).
The aim was to evaluate the drug’s clinical efﬁ  cacy and 
safety in this orphan disease; survival was the primary end 
point, while secondary end points were tumor response and 
time to progression. All patients received weekly iv infusions 
of ranpirnase at an initial dose of 480 g/m2.
Patients (n = 105) with an ECOG performance status 
score of 0–2, were enrolled; the Cancer and Leukemia Group 
B (CALGB) prognostic group criteria (Herndon et al 1998) 
were used to deﬁ  ne treatment target groups (TTGs). This 
study prospectively used an intent-to-treat (ITT) analysis 
that included all patients enrolled, and retrospectively used 
the TTG analysis that included only those patients who 
met the predeﬁ  ned criteria for the CALGB prognostic groups 
Table 2 In vivo activity of ranpirnase in animal models
Model Author Prevalent activity
HT29MDR1 colon cancer xenograft Rybak et al 1996 In association with vincristine, ranpirnase 
overcame MDR1-mediated resistance
M109 Madison mouse carcinoma 
in mice
Mikulski et al 1990 Ranpirnase slowed tumor growth, increas-
ing survival (in the Madison mouse model)
MDA-MB-231 human breast 
cancer in nude mice
Mikulski et al1999 Ranpirnase synergized with doxorubicin, 
increasing survival
Daudi cells given intraperitoneally 
in SCID mice
Newton et al 2001 Ranpirnase synergized with the anti-
CD22 monoclonal antibody epratuzumab, 
increasing survival
H411E rat hepatoma
MCaIV murine adenocarcinoma
FSaII murine ﬁ  brosarcoma
DU145 human prostate cancer in 
nude mice
Lee et al 2000b Ranpirnase inhibited tumor growth
AsPC-1 human pancreatic carci-
noma in nude mice
Lee et al 2003Biologics: Targets & Therapy 2008:2(4) 606
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1–4 combined (n = 81). Using the Kaplan-Meier method, the 
overall median survival time was 6 months (95% conﬁ  dence 
interval [CI]: 4.7–10.0 months) and 8.3 months for the ITT 
populations; the 1- and 2-year survival rates were 34.3% and 
21.6%, respectively, for the ITT population, and 42% and 
26.8% for TTG, respectively. The median survival times for 
the CALGB groups 1–6 were 29.9, 6.6, 5.8, 10.7, 4.5, and 
1.8 months, respectively. As expected, survival was longest 
for the best prognostic group and shortest for the worst 
group. Survival analysis of patients who had prior chemo-
therapy vs those who had not was not signiﬁ  cantly different 
(median survival time: 7.3 vs 5.7 months; 1-year survival 
rate: 33.3 versus 34.9%; 2-year survival rate: 19.7 vs 22.7%; 
log-rank p = 0.971). Patients with better performance status 
and epithelioid histology had, as expected, more favorable 
survival. Among the 81 patients assessable for investi-
gator-assessed tumor response, 4 had partial responses 
(PR), 2 had minor responses (MR), and 35 experienced 
disease stabilization (SD) (Mikulski et al 2002).
Twenty-two patients developed grade 3 (n = 18) or 4 (n = 4) 
adverse events that were considered related to treatment. As 
expected on the basis of the phase I experience, treatment 
was associated with asthenia, ﬂ  u-like symptoms, arthralgia, 
fever, vasodilation (manifesting as ﬂ  ushing with occasional 
hypotension and/or vasovagal reaction), paraesthesias, periph-
eral edema, renal insufﬁ  ciency, and allergic reactions.
This study clearly suggested that ranpirnase mainly acts 
as a cytostatic agent, as do many other molecularly targeted 
drugs. Indeed, conventional radiological measurements and 
commonly used response criteria (eg, the RECIST ones) are 
not be the best way to evaluate the antitumor activity of drugs 
such as ranpirnase, time-dependent end points being more 
useful (Korn et al 2001; Pavlakis and Vogelzang 2006).
As a whole, this phase II trial in MMe clearly suggested 
that ranpirnase may have disease-modifying activity in MMe, 
justifying the subsequent move to phase III.
Phase III studies in malignant 
mesothelioma
Based on positive combination preclinical studies, ranpirnase 
could be combined with either cisplatin or doxorubicin, both 
established active agents for MMe (Vogelzang et al 2005; 
Fennel et al 2008). However, in view of its potential for 
renal toxicity, doxorubicin seemed the obvious choice for 
combination in order to avoid potential overlapping renal 
toxicity with cisplatin.
Thus, in an initial phase III study in MMe, patients were 
randomized to receive ranpirnase (480 g/m2 iv weekly) 
or doxorubicin (60 mg/m2 iv q21 days) using a 3:2 
randomization ratio (Vogelzang et al 2000). This was an 
open-label, multi-center, randomized controlled trial which 
enrolled 154 patients with MMe who were either chemo-
therapy-naïve or had failed one prior chemotherapy regimen; 
patients were stratiﬁ  ed by performance status (0 vs 1) and 
histology (epithelioid vs non-epithelioid). The primary end 
point of the study was overall survival by ITT.
Final results (available on 144 patients, 75 treated with 
ranpirnase and 69 with doxorubicin), showed no signiﬁ  cant 
differences between the two arms (Table 3a).
Analysis by CALGB prognostic groups, however, 
revealed an excess of poor prognosis patients (groups 5 and 6) 
in the ranpirnase arm (37%) compared with the doxorubicin 
arm arm (17%).
A post-hoc analysis was thus performed excluding these 
patients and those with unconﬁ  rmed MMe by centralized 
pathological review (additional n = 5). TTGs were deﬁ  ned 
based on the CALGB prognostic groups, as evaluated in the 
above-mentioned phase II study. The results of this analysis 
clearly favored ranpirnase, as shown in Table 3b; indeed, 
a Cox proportional hazards regression analysis revealed a 
survival risk ratio of 1.34 in favor of ranpirnase treatment 
in the ITT population, allowing for histology, age, sex, 
CALGB prognostic groups and abdominal involvement 
(95% CI: 0.93–1.94; p = 0.12). In the post-hoc TTG analysis, 
the same Cox proportional hazards regression analysis 
revealed a survival risk ratio of 1.60 in favor of ranpirnase 
treatment (95% CI: 1.03–2.50; p = 0.04).
Few grade 3/4 toxicities were observed (Table 4), the most 
commonly reported being asthenia (10.8%), and ranpirnase 
toxicities were mainly reversible on drug discontinuation 
(Vogelzang 2000). Furthermore, owing to protocol-mandated 
dose reduction for renal toxicity, no serious renal toxicity 
Table 3 Results of the ﬁ  rst phase III trial of ranpirnase vs doxorubicin 
in MMe patients according to the patient population considered: ITT 
(a) or TTG (b) (Vogelzang 2000)
a Ranpirnase-treated 
patients
Doxorubicin-treated 
patients
Median survival 8.4 months 8.2 months
1-year survival rate 33.3% 34.8%
2-year survival rate 13.7% 10.9%
b Ranpirnase-treated 
patients
Doxorubicin-treated 
patients
Median survival 11.6 months 9.6 months
1-year survival rate 46.8% 38.6%
2-year survival rate 20.9% 13.2%Biologics: Targets & Therapy 2008:2(4) 607
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was observed, thus supporting the view that ranpirnase, 
when administered with appropriate attention for hypersen-
sitivity and with monitoring and dose adjustment for renal 
impairment, is a relatively safe and well-tolerated treatment 
(Pavlakis and Vogelzang 2006).
After the aforementioned phase III trial, another multi-
center, randomized, controlled, phase III study, to be performed 
on a global scale, was designed: the P30–302 protocol, entitled 
“Onconase® plus Doxorubicin versus Doxorubicin alone for 
patients with malignant pleural or peritoneal mesothelioma who 
have had no more than one prior chemotherapy regimen”.
In this study, patients with proven mesothelioma were 
randomized to receive either doxorubicin 60 mg/m2 iv every 
3 weeks or iv ranpirnase weekly (given at 240 g/m2 in cycle 1, 
to be escalated to 480 g/m2 from cycle 2 in the absence of 
serious toxicity), followed by doxorubicin 60 mg/m2 iv every 
3 weeks. Patients were stratiﬁ  ed according to the CALGB 
prognostic groups (1–4) and histology, and were random-
ized in a 1:1 fashion. The primary end point of the study 
was overall survival. This study has been recently closed to 
enrollment, but its ﬁ  nal results are not yet available.
An interim analysis was performed per protocol at the 
occurrence of 105 deaths. The key ﬁ  ndings were as follows 
(pers comm., Shogen K).
Overall median survival time (MST), the primary 
endpoint of the study, favored the ranpirnase plus doxorubi-
cin treatment group (12 months) over the doxorubicin group 
(10 months). A 2-month improvement in median survival 
has also been observed previously in the TTG analysis 
(N = 104) from the completed phase III single agent study 
that favored the ranpirnase group over the doxorubicin group 
(11.6 months vs 9.6 months).
Other results of this interim analysis included: at 
1 year, 47% of the ranpirnase plus doxorubicin-treated 
subjects were alive compared with 36% of patients treated 
with doxorubicin only. Subjects evaluable for clinical response 
(those with evidence of tumor regression or stabilization of 
disease for a minimum of 3 months) showed a 7-month 
difference in MST (17 vs 10 months) favoring the ranpirnase 
plus doxorubicin group vs the doxorubicin group.
The analysis of safety data revealed that ranpirnase, 
when given with doxorubicin, did not increase the number or 
severity of known doxorubicin-associated side effects. The 
most frequent side effects reported for both treatment groups 
included nausea, fatigue, and alopecia. The incidence of these 
events was comparable for both treatment groups.
Conclusions
Ranpirnase is a ribonuclease endowed with potent antitumor 
properties; its mechanism of action is completely novel since, 
by degrading tRNA, it acts both as a cytotoxic and a cytostatic 
drug; furthermore, owing to both its in vitro synergy with 
other cytotoxic agents, and its tolerability as a single agent, 
it is amenable to combination with traditional chemothera-
peutic drugs, eg, doxorubicin and cisplatin.
Since its early clinical development, it has held great 
promise for the treatment of MMe, where it seems to act 
mainly as a cytostatic agent, thus stabilizing the disease. 
Indeed, ranpirnase proved to be superior to doxorubicin 
within a phase III trial, while preliminary results of another 
large, phase III trial suggest that the combination of 
ranpirnase and doxorubicin could be more effective than 
doxorubicin alone
Ranpirnase appears to be generally well tolerated with 
predicable and reversible toxicity, and with very few serious 
adverse events; furthermore, dose modiﬁ  cations are usually 
required only for changes in renal function.
Unfortunately for the development of the drug, during 
the course of its phase III development, the combination 
of pemetrexed and a platinum derivative emerged as the 
standard ﬁ  rst-line treatment for MMe patients in. This led 
to a slowing of the recruitment into the P30–302 protocol 
Table 4 Grade III and IV toxicities observed in the phase III study of 
ranpirnase vs doxorubicin in MMe (according to the National Cancer 
Institute of Canada [NCIC] classiﬁ  cation) (Vogelzang 2000)
Ranpirnase
G3 G4
Toxicity no. % no. %
Asthenia 9 10.8 1 1.2
Arthralgia/myalgia 4 4.8 0 0
Paresthesias 4 4.8 0 0
Dyspnea 4 4.8 0 0
Edema 2 2.4 0 0
Anaphylactoid 
reaction
0 0 1 1.2
Nausea and 
vomiting
0 0 1 1.2
Doxorubicin
G3 G4
Toxicity no. % no. %
Asthenia 2 4.5 0 0
Fever 2 4.5 1 2.3
Anorexia 1 2.3 0 0
Mucositis 1 2.3 0 0
Nausea and 
vomiting
1 2.3 1 2.3Biologics: Targets & Therapy 2008:2(4) 608
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and clearly reduced the interest for its use as a ﬁ  rst-line 
treatment.
Thus, while waiting the ﬁ  nal results of the above study, 
it appears clear that ranpirnase may ﬁ  nd its niche (in com-
bination with doxorubicin) for second-line therapy of MMe 
(Pavlakis and Vogelzang 2006) where, at present, no standard 
of care exists.
However, the current understanding of its mechanism 
of action, coupled with its favorable toxicity proﬁ  le, char-
acterized by a lack of major toxicities, especially in terms 
of hematology, make ranpirnase an appealing drug to use in 
combination with other anticancer agents, as well as with 
radiotherapy. This could clearly open a new frontier for the 
use of this novel drug in tumor types other than MMe.
Acknowledgments
We gratefully thank Dr. Kuslima Shogen from Alfacell for 
providing, for the purpose of this review, the above summa-
rized preliminary data relative to the still unpublished phase III 
study of doxorubicin plus or minus ranpirnase in MMe.
This work has been supported by the Italian Group for 
Mesothelioma (G.I.Me.) and by Fondazione Buzzi-Unicem
Disclosures
None of the authors has any conflicts of interest to 
disclose.
References
Ardelt W, Mikulski SM, Shogen K. 1991 Amino acid sequence of an 
anti-tumor protein from Rana pipiens oocytes and early embryos. 
Homology to pancreatic ribonucleases. J Biol Chem, 266:245–51.
Ardelt B, Juan G, Burfeind P, et al. 2007. Onconase, an anti-tumor 
ribonuclease, suppresses intracellular oxidative stress. Int J Oncol, 
31:663–9.
Arnold U, Ulbrich-Hofmann R. 2006. Natural and engineered ribonucleases 
as potential cancer therapeutics. Biotechnol Lett, 28:1615–22.
Benito A, Ribó M, Vilanova M. 2005. On the track of antitumour 
ribonucleases. Mol Biosyst, 1:294–302.
Boix E, Wu Y, Vasandani VM, et al. 1996. Role of the N terminus in RNase 
A homologues. Differences in catalytic activity, ribonuclease inhibitor 
interaction and cytotoxicity. J Mol Biol, 257:992–1007.
Bruserud O. 2007. Introduction: RNA and the treatment of human cancer. 
Curr Pharm Biotechnol, 8:318–9.
Carbone M, Emri S, Dogan AU, et al. 2007. A mesothelioma epidemic in 
Cappadocia: scientiﬁ  c developments and unexpected social outcomes. 
Nat Rev Cancer, 7:147–54.
Chun H, Costanzi J, Mittelman A, et al. 1995, Phase I/II trial of onconase 
(ONC) plus tamoxifen (TMX) in patients (pts) with advanced pancreatic 
carcinoma (APC) [abstract]. Proc Am Soc Clin Oncol, 517.
Costanzi J, Sidransky D, Navon A, et al. 2005. Ribonucleases as a novel 
pro-apoptotic anticancer strategy: review of the pre-clinical and clinical 
data for ranpirnase. Cancer Invest, 23:643–50.
D’Alessio G, Di Donato A, Mazzarella L, et al. 1997. Seminal ribonuclease: 
the importance of diversity. In: D’Alessio G, Riordan JF (eds.) 
Ribonucleases: structures and functions. New York, NY, U S A: 
Academic Press. pp. 383–423.
Darzynkiewicz Z, Carter SP, Mikulski SM, et al. 1988. Cytostatic and 
cytotoxic effect of Pannon (P-30 protein), a novel anticancer agent. 
Cell Tissue Kinet, 21:169–82.
Deptala A, Halicka HD, Ardelt B, et al. 1998. Potentiation of tumor necrosis 
factor-induced apoptosis by Onconase. Int J Oncol, 13:11–6.
Fennell DA, Gaudino G, O’Byrne KJ, et al. 2008. Advances in the systemic 
therapy of malignant pleural mesothelioma. Nat Clin Pract Cancer, 
5:136–47.
Halicka DH, Juan G, Ardelt B, et al. 1996. Induction of differentation 
and apoptosis of U937 and HL-60 cells by Onconase: potentiation by 
inhibitors of protein kinases. Proc Am Soc Clin Oncol, 15:18 (abs.).
Herndon JE, Green MR, Chahinian AP, et al. 1998. Factors predictive of 
survival among 337 patients with mesothelioma treated between 1984 
and 1994 by the Cancer and Leukemia Group B. Chest, 113:723–31.
Hofsteenge J. 1997. Ribonuclease inhibitor. In: D’Alessio G, Riordan JF 
(eds.). Ribonucleases: structures and functions. New York, NY, USA: 
Academic Press. pp. 621–58.
Iordanov MS, Ryabinina OP, Wong J et al. 2000. Molecular determinants 
of apoptosis induced by the cytotoxic ribonuclease onconase: evidence 
for cytotoxic mechanisms different from inhibition of protein synthesis. 
Cancer Res, 60:1983–94.
Iordanov MS, Wong J, Newton Dl, et al. 2000. Differential requirements for 
the stress-activated protein kinase/c-Jun NH(2) terminal kinase in RNA 
damage-induced apoptosis in primary and in immortalized ﬁ  broblasts. 
Mol Cell Biol Res Commun, 4:122–8.
Irie M, Nitta K, Nonaka T. 1998. Biochemistry of frog ribonucleases. Cell 
Mol Life Sci, 54:775–84.
Juan G, Ardelt B, Li X, et al. 1998. G1 arrest of U937 cells by onconase 
is associated with suppression of cyclin D3 expression, induction of 
p16INK4A, p21WAF1/CIP1 and p27KIP and decreased pRB phosphorylation. 
Leukemia, 12:1241–8.
Kim DH, Kim EJ, Kalota A, et al. 2007. Possibile mechanisms of improved 
radiation response by cytotoxic RNase, Onconase, on A549 human lung 
cancer xenografts of nude mice. Adv Exp Med Biol, 599:53–9.
Korn EL, Arbuck SG, Pluda JM, et al. 2001. Clinical trial designs 
for cytostatic agents: are new approaches needed? J Clin Oncol, 
19:265–72.
Ledoux L, Balthus E. 1954. Action de la ribonucléase sur les cellules du 
carcinoma d’Erlich. Experientia, 10:500–1.
Ledoux L. 1955. Action of ribonuclease on two solid tumours in vivo. 
Nature, 176:36–7.
Lee I, Lee YH, Mikulski SM, et al. 2000. Enhanced cellular radiation 
sensitivity of androgen-independent human prostate tumor cells by 
Onconase. Anticancer Res, 20:1037–40.
Lee I, Lee YM, Mikulski SM, et al. 2000. Tumoricidal effects of Onconase 
on various tumors. J Surg Oncol, 73:164–71.
Lee I, Lee YM, Mikulski SM, et al. 2003. Effect of Onconase ± tamoxifen 
on ASPC-1 human pancreatic tumors in nude mice. Adv Exp Med 
Biol, 530:187–96.
Lee I, Kalota A, Gerwitz AM, et al. 2007. Antitumor efﬁ  cacy of the cytotoxic 
RNase, Ranpirnase, on A549 human lung cancer xenografts of nude 
mice. Anticancer Res, 27:299–308.
Lee I, Kim DH, Sunar U, et al. 2007. The therapeutic mechanism of 
ranpirnase-induced enhancement of radiation response on A549 human 
lung cancer. In Vivo, 21:721–8.
Lee I, Shogen K. 2008. Mechanism of enhanced tumoricidal efﬁ  cacy of 
multiple small dosages of Ranpirnase, the novel cytotoxic ribonuclease, 
on lung cancer. Cancer Chemother Pharmacol, 62:337–46.
Lee JE, Raines RT. 2008. Ribonucleases as novel chemotherapeutics: the 
ranpirnase example. BioDrugs, 22:53–8.
Leland PA, Schultz LW, Kim BM, et al. 1998. Ribonuclease A variants with 
potent cytotoxic activity. Proc Natl Acad Sci U S A, 95:10407–12.
Leland PA, Raines RT. 2001. Cancer chemotherapy – ribonucleases to the 
rescue. Chem Biol, 8:405–13.
Michaelis M, Cinatl J, Anand P, et al. 2007. Onconase induces caspase-
independant cell death in chemoresistant neurobastoma cells. Cancer 
Lett, 250:107–16.Biologics: Targets & Therapy 2008:2(4) 609
Ranpirnase in malignant mesothelioma
Mikulski SM, Ardelt W, Shogen K, et al. 1990. Striking increase of survival 
of mice bearing M109 Madison carcinoma treated with a novel protein 
from amphibian embryos. J Natl Cancer Inst, 82:151–3.
Mikulski SM, Viera A, Ardelt W, et al. 1990. Tamoxifen and triﬂ  uoro-
perazine (Stelazine) potenziate cytostatic/cytotoxic effects of P-30 
protein, a novel protein possessing anti-tumour activity. Cell Tissue 
Kinet, 23:237–46.
Mikulski SM, Viera A, Shogen K. 1992. In vitro synergism between a 
novel amphibian oocytic ribonuclease (Onconase) and tamoxifen, 
lovastatin and cisplatin, in human OVCAR-3 ovarian carcinoma cell 
line. Int J Oncol, 1:77–85.
Mikulski SM, Grossman AM, Carter PW, et al. 1993. Phase I human clinical 
trial of Onconase (P-30 protein) administered intravenously on a weekly 
schedule in cancer patients with solid tumors. Int J Oncol, 3:57–64.
Mikulski SM, Chun HG, Mittelman A, et al. 1995. Relationship between 
response rate and median survival in patients with advanced non-small 
cell lung cancer: comparison of – Onconase® with other anticancer 
agents. Int J Oncol, 6:889–97.
Mikulski SM, Newton DL, Wiltrout RH, et al. 1999. Onconase and 
doxorubicin synergy in prolonging survival of MDA-MB-231 human 
breast cancer-bearing nude mice [abstract]. Proc Am Assoc Cancer 
Res, 40:491(abs. 3246).
Mikulski SM, Costanzi JJ, Vogelzang NJ, et al. 2002. Phase II trial of a 
single weekly intravenous dose of ranpirnase in patients with unresect-
able malignant mesothelioma. J Clin Oncol, 20:274–81.
Mosimann SC, Johns KL, Ardelt W, et al. 1992. Comparative molecular 
modeling and crystallization of P-30 protein: a novel antitumor protein 
of Rana pipiens oocytes and early embryos. Proteins, 14:392–400.
Newton DL, Hansen HJ, Mikulski SM, et al. 2001. Potent and speciﬁ  c anti-
tumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential 
for the treatment of non-Hodgkin lymphoma. Blood, 97:528–35.
Pavlakis N, Vogelzang NJ. 2006. Ranpirnase – an antitumour ribonuclease: 
its potential role in malignant mesothelioma. Expert Opin Biol Ther, 
6:391–9.
Peto J, Recarli A, La Vecchia C, et al. 1999. The European mesothelioma 
epidemic. Br J Cancer, 79:666–72.
Puccio C, Mittelman A, Chun H et al. 1996. A new anticancer RNase 
(Onconase): clinical trial in patients (pts) with breast cancer (BC) 
[abstract]. Proc Am Soc Clin Oncol, 242.
Ramos-Nino ME, Vianale G, Sabo-Attwood T, et al. 2005. Human 
mesothelioma cells exhibit tumor cell-specific differences in 
phosphatidylinositol 3-kinase/AKT activity that predict the efﬁ  cacy 
of Onconase. Mol Cancer Ther, 4:835–42.
Riordan JF. Structure and function of angiogenin. 1997. In: D’Alessio G, 
Riordan JF (eds.). Ribonucleases: structures and functions. New York, 
NY, U S A: Academic Press. pp. 445–89.
Rybak SM, Pearson JW, Foglerwe, et al. 1996. Enhancement of 
vincristine cytotoxicity in drug-resistant cells by simultaneous 
treatment with onconase, an antitumor ribonuclease. J Natl Cancer 
Inst, 88:747–53.
Shacter E, Williams JA, Hinson RM, et al. 2000. Oxidative stress interferes 
with cancer chemotherapy: inhibition of lymphoma cell apoptosis and 
phagocytosis. Blood, 96:307–13.
Vasandani VM, Wu YN, Mikulski SM, et al. 1996. Molecular determinants 
in the plasma clearance and tissue distribution of ribonucleases of the 
ribonuclease A superfamily. Cancer Res, 56:4180–6.
Vasandani VM, Burris JA, Sung C. 1999. Reversible nephrotoxicity of 
onconase and effect of lysine pH on renal onconase uptake. Cancer 
Chemother Pharmacol, 44:164–9.
Vogelzang N, Taub R, Shin D, et al. 2000. Phase III randomized trial of 
onconase (ONC) versus doxorubicin (DOX) in patients (Pts) with 
unresectable malignant mesothelioma (UMM): analysis of survival 
[abstract]. Proc Am Soc Clin Oncol, 2274.
Vogelzang NJ, Aklilu M, Stadler WM, et al. 2001. A Phase II trial 
of weekly intravenous ranpirnase (Onconase), a novel ribonucle-
ase in patients with metastatic kidney cancer. Invest New Drugs, 
3:255–60.
Vogelzang NJ, Porta C, Mutti L. 2005. New agents in the management of 
advanced mesothelioma. Semin Oncol, 32:336–50.
Wu Y, Mikulski SM, Ardelt W, et al. 1993. A cytotoxic ribonuclease. 
Study of the mechanism of onconase cytotoxicity. J Biol Chem, 
268:10686–93.